GlassScriptPhysician profile
Usha K Nuthi
NPI 1497722524
$3,542.27
in general payments reported to CMS, 2019-2025
29 companies · $79.79 in 2025
The $79.79 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $340 · 2021: $1,178 · 2023: $76.96 · 2025: $79.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $430.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $425.74 | 2019-2021 | |
| Amgen INC. | $314.46 | 2019-2021 | |
| Emd Serono, INC. | $302.67 | 2019-2021 | |
| Allergan, INC. | $243.92 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $226.59 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $197.91 | 2021 | |
| Ucb, INC. | $170.52 | 2019-2021 | |
| Lilly USA, LLC | $139.87 | 2019-2021 | |
| Genzyme Corporation | $131.89 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $121.85 | 2021 | |
| Abbvie INC. | $117.70 | 2019-2021 | |
| Eisai INC. | $92.43 | 2019 | |
| Tg Therapeutics, INC. | $79.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $76.96 | 2023 | Andexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $69.32 | 2021 | |
| Adamas Pharmaceuticals, INC. | $54.14 | 2019-2021 | |
| Biogen, INC. | $52.47 | 2019-2021 | |
| Boston Scientific Corporation | $41.39 | 2021 | |
| Banner Life Sciences, LLC | $39.20 | 2021 | |
| Celgene Corporation | $37.22 | 2021 | |
| Acadia Pharmaceuticals INC | $32.95 | 2019-2021 | |
| Nevro Corp. | $31.96 | 2019 | |
| Kyowa Kirin, INC. | $24.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.14 | 2021 | |
| Pfizer INC. | $21.57 | 2019 | |
| Greenwich Biosciences, INC. | $15.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.27 | 2021 | |
| Merz North America, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Nuthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.